Clinical Trial Results:
ESTUDIO PILOTO PARA COMPARAR LOS PARÁMETROS FARMACOCINÉTICOS EN PLASMA E INTRACELULARES DE RALTEGRAVIR ADMINISTRADO UNA VEZ AL DÍA EN PACIENTES ADULTOS INFECTADOS POR EL VIH (Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients)
Summary
|
|
EudraCT number |
2009-014313-27 |
Trial protocol |
ES |
Global end of trial date |
15 Dec 2009
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Jan 2018
|
First version publication date |
05 Jan 2018
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
RAL-IC
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00995241 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Fundació Lluita contra la SIDA
|
||
Sponsor organisation address |
Crta de Canyet s/n, Badalona, Spain, 08916
|
||
Public contact |
CRA, Fundació Lluita contra la SIDA, +34 93 497 84 14, jtoro@flsida.org
|
||
Scientific contact |
CRA, Fundació Lluita contra la SIDA, +34 93 497 84 14,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
15 Dec 2009
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 Dec 2009
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Dec 2009
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The aim of this study was to evaluate the plasma and intracellular pharmacokinetics of raltegravir in HIV-infected patients receiving once-daily raltegravir.
|
||
Protection of trial subjects |
not specific
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
16 Nov 2009
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 5
|
||
Worldwide total number of subjects |
5
|
||
EEA total number of subjects |
5
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
5
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Patients whose HIV-1 RNA load was <50 copies/ml and who were receiving antiretroviral monotherapy with lopinavir-ritonavir at 400/100 mg twice-daily for at least 4 weeks prior to their inclusion were enrolled. | ||||||
Pre-assignment
|
|||||||
Screening details |
Five HIV-infected patients were enrolled | ||||||
Period 1
|
|||||||
Period 1 title |
overall (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Experimental group | ||||||
Arm description |
Lopinavir-ritonavir plus raltegravir | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
lopinavir/ritonavir (LPV/r)
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
400/100 mg twice-daily
|
||||||
Investigational medicinal product name |
raltegravir
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
800 mg once daily from days 0 to 10
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
overall
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Experimental group
|
||
Reporting group description |
Lopinavir-ritonavir plus raltegravir |
|
|||||||||||||
End point title |
Pharmacokinetic parameters for raltegravir: maximum concentrations [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
day 10
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: one single arm study |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Pharmacokinetic parameters for raltegravir: concentrations at the end of the dosing interval [2] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
day 10
|
||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: one single arm study |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
pharmacokinetic parameters for raltegravir: the geometric mean [3] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
day 10
|
||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: one single arm study |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||
Adverse events information [1]
|
|||||||||||
Timeframe for reporting adverse events |
from baseline to week 4
|
||||||||||
Assessment type |
Non-systematic | ||||||||||
Dictionary used for adverse event reporting
|
|||||||||||
Dictionary name |
DAIDS AE GRADING TAB | ||||||||||
Dictionary version |
1.0
|
||||||||||
Reporting groups
|
|||||||||||
Reporting group title |
experimental group
|
||||||||||
Reporting group description |
- | ||||||||||
|
|||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||
|
|||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: no adverse events (neither non-serious nor serious adverse events) occured in this clinical trial |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
04 Nov 2009 |
Changes in the supply, packaging, labeling and storage of the investigational product |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |